Does the media refer more to LGVN or YARW?

In the previous week, Longeveron and Longeveron both had 1 articles in the media. Yarrow Bioscience's average media sentiment score of 0.84 beat Longeveron's score of 0.00 indicating that Yarrow Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Yarrow Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LGVN or SERA more profitable?

Longeveron has a net margin of -1,977.59% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets Longeveron -1,977.59% -223.19% -150.20% Sera Prognostics -47,475.72% -46.71% -34.06%

Does the media refer more to LGVN or SERA?

In the previous week, Longeveron and Longeveron both had 1 articles in the media. Sera Prognostics' average media sentiment score of 0.59 beat Longeveron's score of 0.00 indicating that Sera Prognostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sera Prognostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRDF or LGVN?

In the previous week, Cardiff Oncology had 1 more articles in the media than Longeveron. MarketBeat recorded 2 mentions for Cardiff Oncology and 1 mentions for Longeveron. Cardiff Oncology's average media sentiment score of 0.00 equaled Longeveron'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Longeveron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, OKYO or LGVN?

OKYO Pharma has higher earnings, but lower revenue than Longeveron. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$8.95M N/A N/A Longeveron $1.20M 17.49 -$22.70M -$0.99 N/A

Is OKYO or LGVN more profitable?

OKYO Pharma has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. OKYO Pharma's return on equity of 0.00% beat Longeveron's return on equity. Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A Longeveron -1,977.59% -223.19% -150.20%

Does the media refer more to OKYO or LGVN?

In the previous week, OKYO Pharma and OKYO Pharma both had 1 articles in the media. OKYO Pharma's average media sentiment score of 1.89 beat Longeveron's score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OKYO Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Longeveron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to GANX or LGVN?

In the previous week, Gain Therapeutics had 9 more articles in the media than Longeveron. MarketBeat recorded 10 mentions for Gain Therapeutics and 1 mentions for Longeveron. Gain Therapeutics' average media sentiment score of 0.27 beat Longeveron's score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Longeveron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Longeveron (LGVN) Competitors

$6.58 -0.20 (-2.95%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$6.65 +0.07 (+1.06%)

As of 04:00 AM Eastern

Compare

LGVN vs. YARW, SERA, CRDF, OKYO, and GANX

Should you buy Longeveron stock or one of its competitors? Longeveron's main competitors and comparable companies include Yarrow Bioscience (YARW), Sera Prognostics (SERA), Cardiff Oncology (CRDF), OKYO Pharma (OKYO), and Gain Therapeutics (GANX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Longeveron compare to Yarrow Bioscience?

Longeveron (NASDAQ:LGVN) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Longeveron has higher revenue and earnings than Yarrow Bioscience. Longeveron is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	17.49	-$22.70M	-$0.99	N/A
Yarrow Bioscience	$570K	135.14	-$26.48M	-$14.64	N/A

Longeveron has a net margin of -1,977.59% compared to Yarrow Bioscience's net margin of -4,726.21%. Yarrow Bioscience's return on equity of -84.40% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,977.59%	-223.19%	-150.20%
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

Longeveron currently has a consensus target price of $80.00, indicating a potential upside of 1,115.81%. Yarrow Bioscience has a consensus target price of $58.00, indicating a potential upside of 101.04%. Given Longeveron's higher probable upside, equities research analysts clearly believe Longeveron is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Yarrow Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Longeveron has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market. Comparatively, Yarrow Bioscience has a beta of 2.01, meaning that its share price is 101% more volatile than the broader market.

In the previous week, Longeveron and Longeveron both had 1 articles in the media. Yarrow Bioscience's average media sentiment score of 0.84 beat Longeveron's score of 0.00 indicating that Yarrow Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longeveron	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Yarrow Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10.0% of Longeveron shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 7.4% of Longeveron shares are held by insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Yarrow Bioscience beats Longeveron on 8 of the 15 factors compared between the two stocks.

How does Longeveron compare to Sera Prognostics?

Longeveron (NASDAQ:LGVN) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

10.0% of Longeveron shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 7.4% of Longeveron shares are held by company insiders. Comparatively, 11.3% of Sera Prognostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Longeveron currently has a consensus price target of $80.00, suggesting a potential upside of 1,115.81%. Sera Prognostics has a consensus price target of $5.50, suggesting a potential upside of 177.78%. Given Longeveron's higher probable upside, equities research analysts plainly believe Longeveron is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Longeveron has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

Longeveron has a net margin of -1,977.59% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Longeveron	-1,977.59%	-223.19%	-150.20%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Longeveron has higher revenue and earnings than Sera Prognostics. Longeveron is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longeveron	$1.20M	17.49	-$22.70M	-$0.99	N/A
Sera Prognostics	$80K	976.39	-$31.93M	-$0.67	N/A

In the previous week, Longeveron and Longeveron both had 1 articles in the media. Sera Prognostics' average media sentiment score of 0.59 beat Longeveron's score of 0.00 indicating that Sera Prognostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Longeveron	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sera Prognostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sera Prognostics beats Longeveron on 10 of the 15 factors compared between the two stocks.

How does Longeveron compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Longeveron has a net margin of -1,977.59% compared to Cardiff Oncology's net margin of -7,885.43%. Cardiff Oncology's return on equity of -103.10% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%
Longeveron	-1,977.59%	-223.19%	-150.20%

Cardiff Oncology currently has a consensus price target of $7.50, suggesting a potential upside of 594.44%. Longeveron has a consensus price target of $80.00, suggesting a potential upside of 1,115.81%. Given Longeveron's higher probable upside, analysts plainly believe Longeveron is more favorable than Cardiff Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cardiff Oncology has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market.

In the previous week, Cardiff Oncology had 1 more articles in the media than Longeveron. MarketBeat recorded 2 mentions for Cardiff Oncology and 1 mentions for Longeveron. Cardiff Oncology's average media sentiment score of 0.00 equaled Longeveron'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Longeveron	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 8.8% of Cardiff Oncology shares are owned by insiders. Comparatively, 7.4% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Longeveron has higher revenue and earnings than Cardiff Oncology. Longeveron is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	142.40	-$45.85M	-$0.60	N/A
Longeveron	$1.20M	17.49	-$22.70M	-$0.99	N/A

Summary

Cardiff Oncology beats Longeveron on 10 of the 15 factors compared between the two stocks.

How does Longeveron compare to OKYO Pharma?

OKYO Pharma (NASDAQ:OKYO) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

OKYO Pharma presently has a consensus target price of $5.67, suggesting a potential upside of 265.59%. Longeveron has a consensus target price of $80.00, suggesting a potential upside of 1,115.81%. Given Longeveron's higher possible upside, analysts clearly believe Longeveron is more favorable than OKYO Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 7.4% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

OKYO Pharma has higher earnings, but lower revenue than Longeveron.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A
Longeveron	$1.20M	17.49	-$22.70M	-$0.99	N/A

OKYO Pharma has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. OKYO Pharma's return on equity of 0.00% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Longeveron	-1,977.59%	-223.19%	-150.20%

In the previous week, OKYO Pharma and OKYO Pharma both had 1 articles in the media. OKYO Pharma's average media sentiment score of 1.89 beat Longeveron's score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OKYO Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Longeveron	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OKYO Pharma has a beta of 0.03, meaning that its stock price is 97% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

Summary

OKYO Pharma beats Longeveron on 9 of the 12 factors compared between the two stocks.

How does Longeveron compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by insiders. Comparatively, 7.4% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Gain Therapeutics currently has a consensus target price of $7.50, suggesting a potential upside of 312.09%. Longeveron has a consensus target price of $80.00, suggesting a potential upside of 1,115.81%. Given Longeveron's higher probable upside, analysts plainly believe Longeveron is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Longeveron	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Gain Therapeutics has higher earnings, but lower revenue than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,588.50	-$20.16M	-$0.50	N/A
Longeveron	$1.20M	17.49	-$22.70M	-$0.99	N/A

Gain Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, Longeveron has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market.

Gain Therapeutics has a net margin of 0.00% compared to Longeveron's net margin of -1,977.59%. Gain Therapeutics' return on equity of -161.59% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Longeveron	-1,977.59%	-223.19%	-150.20%

In the previous week, Gain Therapeutics had 9 more articles in the media than Longeveron. MarketBeat recorded 10 mentions for Gain Therapeutics and 1 mentions for Longeveron. Gain Therapeutics' average media sentiment score of 0.27 beat Longeveron's score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Longeveron	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Gain Therapeutics beats Longeveron on 12 of the 16 factors compared between the two stocks.

Get Longeveron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LGVN vs. The Competition

Export

Metric	Longeveron	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$21.62M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.66	12.66	273.29	25.25
Price / Sales	17.49	1,342.79	623.67	97.64
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	2.02	16.39	12.92	6.14
Net Income	-$22.70M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-2.08%	0.36%	0.60%	-0.27%
1 Month Performance	-11.33%	8.53%	5.72%	0.68%
1 Year Performance	-12.04%	52.66%	25.33%	14.84%

Longeveron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LGVN Longeveron	1.507 of 5 stars	$6.58 -2.9%	$80.00 +1,115.8%	-19.4%	$21.62M	$1.20M	N/A	20
YARW Yarrow Bioscience	2.2927 of 5 stars	$30.98 -6.0%	$58.00 +87.2%	N/A	$82.72M	$570K	N/A	30	News Coverage Short Interest Increase High Trading Volume
SERA Sera Prognostics	2.5701 of 5 stars	$2.08 -1.9%	$5.50 +164.4%	-41.8%	$82.06M	$80K	N/A	120
CRDF Cardiff Oncology	1.9598 of 5 stars	$1.03 +3.7%	$7.50 +628.2%	-44.9%	$80.12M	$590K	N/A	20
OKYO OKYO Pharma	3.1393 of 5 stars	$1.51 -0.7%	$5.67 +275.3%	-31.7%	$79.25M	N/A	N/A	7	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LGVN) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Longeveron (LGVN) Competitors

LGVN vs. YARW, SERA, CRDF, OKYO, and GANX

How does Longeveron compare to Yarrow Bioscience?

Summary

How does Longeveron compare to Sera Prognostics?

Summary

How does Longeveron compare to Cardiff Oncology?

Summary

How does Longeveron compare to OKYO Pharma?

Summary

How does Longeveron compare to Gain Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN vs. The Competition

Longeveron Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Longeveron (LGVN) Competitors

LGVN vs. YARW, SERA, CRDF, OKYO, and GANX

How does Longeveron compare to Yarrow Bioscience?

Which has stronger earnings & valuation, LGVN or YARW?

Is LGVN or YARW more profitable?

Do analysts prefer LGVN or YARW?

Which has more risk and volatility, LGVN or YARW?

Does the media refer more to LGVN or YARW?

Do insiders and institutionals believe in LGVN or YARW?

Summary

How does Longeveron compare to Sera Prognostics?

Do insiders & institutionals hold more shares of LGVN or SERA?

Do analysts recommend LGVN or SERA?

Which has more risk and volatility, LGVN or SERA?

Is LGVN or SERA more profitable?

Which has better earnings and valuation, LGVN or SERA?

Does the media refer more to LGVN or SERA?

Summary

How does Longeveron compare to Cardiff Oncology?

Is CRDF or LGVN more profitable?

Do analysts prefer CRDF or LGVN?

Which has more risk & volatility, CRDF or LGVN?

Does the media prefer CRDF or LGVN?

Do institutionals & insiders hold more shares of CRDF or LGVN?

Which has better earnings and valuation, CRDF or LGVN?

Summary

How does Longeveron compare to OKYO Pharma?

Do analysts prefer OKYO or LGVN?

Do institutionals and insiders have more ownership in OKYO or LGVN?

Which has stronger earnings and valuation, OKYO or LGVN?

Is OKYO or LGVN more profitable?

Does the media refer more to OKYO or LGVN?

Which has more risk and volatility, OKYO or LGVN?

Summary

How does Longeveron compare to Gain Therapeutics?

Do institutionals & insiders believe in GANX or LGVN?

Do analysts prefer GANX or LGVN?

Which has stronger earnings and valuation, GANX or LGVN?

Which has more volatility & risk, GANX or LGVN?

Is GANX or LGVN more profitable?

Does the media refer more to GANX or LGVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN vs. The Competition

Longeveron Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools